论文信息 - 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial - 字舞流文

787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial

A. Hauschild | S. Haferkamp | D. Schadendorf | S. Ugurel | K. Drexler | R. Gutzmer | E. Livingstone | L. Zimmer | J. Hassel | P. Mohr | F. Kiecker | J. Becker | M. Fluck | M. Garzarolli | I. Grimmelmann | F. Meier | S. Eckhardt | I. Thomas | T. Eigentler | U. Leiter-Stoppke